Monday, April 17, 2017

Xencor Names New Board Member

Monrovia-based biopharmaceuticals developer Xencor announced this morning that it has named Kevin Gorman, ph.D., to its board of directors. Gorman is the CEO of Neurocrine Biosciences, where he has been since 1993; he previously was an investor at Avalon Medical Partners, L.P. Gorman replaces director Robert Baltera, Jr., who the company said will not stand for re-election to its board.

---